论文部分内容阅读
目的探讨心钠素（ＡＮＰ）在高血压发病中的作用。方法５２例原发性高血压（ＥＨ）患者，随机分组，应用硝苯地平或卡托普利治疗２周前后，测定血浆、唾液、尿液ＡＮＰ含量的变化，并与健康组对照。结果治疗前患者血浆、唾液、尿液中ＡＮＰ均高于对照组（Ｐ＜０．０１）。治疗２周后，高血压组ＳＢＰ、ＤＢＰ和血、唾液、尿液中ＡＮＰ较治疗前明显降低（Ｐ＜０．０１），而治疗组间比较差异无显著性（Ｐ＞０．０５），且唾液和尿液中ＡＮＰ与血浆中浓度有同样变化趋势。结论硝苯地平和卡托普利可能是通过抑制ＡＮＰ的产生和释放的某个环节而发挥其降压效果的。
Objective To investigate the role of atrial natriuretic peptide (ANP) in the pathogenesis of hypertension. Methods Fifty-two patients with essential hypertension (EH) were randomly divided into two groups. Before and after treatment with nifedipine or captopril for two weeks, the changes of ANP in plasma, saliva and urine were measured and compared with healthy controls. Results Before treatment, ANP in plasma, saliva and urine were higher than those in control group (P <0.01). After 2 weeks of treatment, the SBP, DBP, blood, saliva and urine ANP in hypertension group were significantly lower than those before treatment (P <0.01), but there was no significant difference between the two groups (P> 0.05) And saliva and urine ANP and plasma concentrations have the same trend. Conclusion Nifedipine and captopril may exert their antihypertensive effects by inhibiting the production and release of ANP.